Research Progress of Serum VEGF and FAS in Prognosis of Gastric Cancer

Hou Jianzhang; Zhang Shuli; Yuan Jianlei; Li Hongyan; Hou Zhenjiang

doi:doi:10.11648/j.ajcem.20231102.13

| Peer-Reviewed

Research Progress of Serum VEGF and FAS in Prognosis of Gastric Cancer

Hou Jianzhang, Zhang Shuli, Yuan Jianlei, Li Hongyan, Hou Zhenjiang

Published in American Journal of Clinical and Experimental Medicine (Volume 11, Issue 2)

Received: 14 March 2023 Accepted: 18 April 2023 Published: 20 April 2023

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Vascular endothelial growth factor (VEGF) is an important factor to promote endothelial cell division and angiogenesis. In physiological conditions, the expression level of VEGF in human tissues is very low. Ischemia, hypoxia and many tumors can promote the synthesis and secretion of VEGF, and its expression level is related to the degree of vascularization of tumors, the proliferation, growth and metastasis of tumor cells. Fatty acid synthase (FAS) is a key enzyme for endogenous fatty acid synthesis, which is expressed at a low level in normal tissue cells, while FASN in a variety of tumor cells is continuously highly expressed to meet the energy needs of cell proliferation and the excessive demand for rapid proliferation of tumor cells to form cell membrane lipids. A large amount of research shows that VEGF and FAS play an important role in the development and development of many tumors, and the abnormally high expression in tumor tissue cells is positively correlated with serum VEGF and FAS levels, which is closely related to the prognosis of tumors. Gastric cancer (GC) is one of the most common clinical malignant tumors of the digestive tract, and its incidence and mortality have shown an increasing trend in recent years, and the prognosis is poor, seriously endangering human health. The biological properties of GC are related to the level of VEGF and FAS expression in tissues and serum. This article reviews the research progress of VEGF and FAS, their expression in GC and their prognosis.

Published in	American Journal of Clinical and Experimental Medicine (Volume 11, Issue 2)
DOI	10.11648/j.ajcem.20231102.13
Page(s)	39-46
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Vascular Endothelial Growth Factor, Fatty Acid Synthase, Serum, Gastric Cancer, Prognosis

References

[1]	Hou Jianzhang, Li Yong. Relationship Between the Expression of S100P in Gastric Cancer Tissue and Clinical Pathology [J]. American Journal of Clinical and Experimental Medicine, 2021, 9 (3): 55-64.
[2]	Song ZH, Xu XN, Li KL, et al., Research progress on etiology of gastric cancer [J]. Chin Med J Metall Indus, 2020, 37 (5): 509-511.
[3]	Song J, Ma SJ, Luo JH, et al. Melatonin induces the apoptosis andinhibits the proliferation of human gastric cancer cells via blockadeof the AKT/MDM2 pathway. [J]. Oncology Reports. 2018, 39 (4): 1975-1983.
[4]	Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer [J]. Lancet, 2020, 396: 635-648.
[5]	Yang L, Hou JZ, Hou ZJ. Progress of vascular endothelial growth factor and its receptor in gastric cancer [J]. Chinese medical equipment, 2014, 11 (4): 68-69.
[6]	Apte RS, Chen DS, Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development [J]. Cell, 2019, 176 (6): 1248-1264.
[7]	Karaman S, Lepp$nen VM, Alitalo K. Vascular endothelial growth factor signaling in development and disease [J]. Development, 2018, 145 (14): 1507-1513.
[8]	Wang X, Liu XT, Zhou ST, et al. Detection and Clinical Significance of Coagulation Index and VEGF in Patients with Acute Leukemia [J]. Med Reca, 2022 28 (1): 184-189.
[9]	HoU ZJ, Hou JZ. Progress of Vascular Endothelial Growth Factor and its Receptor in Esophageal Cancer [J]. Med Reca, 2010, 16 (17): 2640-2642.
[10]	Qin F, Wang XB, Gong JP. The regulatory mechanism of fatty acid synthetase expre-ssion in tumor [J]. J Med Mole Biolo, 2010, 7 (5): 453-456.
[11]	LuO JX, Li CF, Cu XH, et al. Advances in fatty acid synthetase genes [J]. Chinese animal husbandry and veterinary medicine, 2011, 38 (6): 118-122.
[12]	Lu Z, Yang HJ, ShI Kai. Regulation of fatty acid synthetase gene expression [J]. Sichuan J Anato, 2009, 17 (2): 31-35.
[13]	Wu YX, Zhang XZ, Yu JJ, et al. Effect of silencing fatty acid synthase gene (FASN) by siRNA interference on proliferation of human esophageal cancer cells [J]. J Clin Med Prac, 2013, 17 (19): 7-10.
[14]	Li XJ, Zhang QH, Luo T, et al. Correlation and Significance of Peroxidase and VEGF mRNA Expression in Gastric Carcinoma [J]. Chin J Bases Clin Gene Surg, 2008, 15 (7): 498-502, 510.
[15]	Wang HL, Luo K, Zhang XF, et al. The Correlation between Serun VEGF level and Tissue Expression in Gastric Cancer and Their Clinical Significance [J]. Lab Immuno-assays & Clin Med, 2009, 16 (2): 77-78.
[16]	Xu YY, Wang ZB, Li C. The clinical discussion: expression of FAS in colorectal carci-noma tissues and relationship with clinical staging about expression in serum [J]. Conte Med, 2017, 23 (15): 26-28.
[17]	Guo W, Jin YS, Niu N, et al. Expression of Fas in bladder cancer and its clinical significance [J]. Mode Onco, 2018, 26 (24): 3990-3993.
[18]	Li HY, Zhang SL, HouJZ. The Vascular Endothelial Growth Factor’s Expression in Gastric Cancer and Progress in Prognostic Research [J]. American Journal of Biomedical and Life Sciences, 2021, 9 (5): 239-247.
[19]	Hou JZ, Zhang SL, Yuan JL, et al. Research Progress of Fatty Acid Synthase in Digestive Tract Tumors [J]. Scie J Public Health, 2022, 10 (5): 214-222.
[20]	Mao ZB, Xiao MB, Huang JF, et al. Significance of Vascular endothelial growth factor in serum of patients with gastric cancer [J]. World Chin J Diges, 2002, 10 (10): 1220-1221.
[21]	Karayiannakis AJ, Bolanakia H, SyrigosKN, et al. Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis [J]. Cancer Lett, 2003, 194 (1): 119-124.
[22]	ZhoU HY, Ye GX, Wang SW, et al. Clinical study on VEGF levels in serum and tumor tissues of patients with gastric cancer [J]. World Journal of Cancer, 2004, 3 (4): 349-350.
[23]	Hu M, Fan ZL, Wang XH. Expression and significance of serum vascular endothelial growth factor in patients with gastric cancer [J]. J Qinghai Med Colle, 2008, 29 (1): 36-38.
[24]	Kang SR, Li J. The Determination of Serum Vascular endothelial growth factor and microvessel density in Gastric Cancer [J]. Acta Acad Med Nei Mongo 2009, 31 (1): 13-18.
[25]	Yin HQ, Duan Y‚Xu LJ. Determination of Serum VEGF and clinical significance in patients with Stomach Carcinoma [J]. Chin Gener Prac, 2009, 7 (11): 1171-1172.
[26]	Mysliwiec P, Pawlak K, Bandurski R, et al. Soluble angiogenesis markers in gastric tumor patients [J]. Folia Histo-chem Cytobiol, 2009, 47 (1): 81-86.
[27]	Hǎlmaciu I, Gurzu S, Dobreanu M, et al. The most studied VEGF molecule is VEGF-A (Vascular Endothelial Growth Factor). Its involvement in various neoplastic processes represents an intensely controversial hypothesis [J]. Rev Med Chir Soc Med Nat Iasi, 2012, 116 (2): 446-451.
[28]	Lei Liu, Ma XL, Xiao ZL, et al. Prognostic value of vascular endothelial growth factor expression in resected gastric cancer [J]. Asian Pac J Cancer Prev. 2012, 13 (7): 3089-3097.
[29]	Wang TB, Deng MH, Qiu WS. Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer [J]. World J Gastroenterol 2007, 13 (12): 1794-1798.
[30]	Wu EH. Clinical study of serum VEGF-A and VEGF-C in patients with gastric cancer [D]. 2008, Master's thesis of Shanghai Jiao Tong University.
[31]	Zhou CR, Zhang MY, Wang CG, et al. Expression and significance of serum vascular endothelial growth factor C in advanced gastric carcinoma [J]. J Sichuan Med, 2010, 31 (11): 1587-1589.
[32]	Wang W, Wang CG, HU SC, et al. Expression and significance of serum vascular endothelial growth factor D in gastric carcinoma patients at advanced stage [J]. Chin Trop Med, 2010, 10 (2): 207-208.
[33]	Shen YL, Ren ZH. Changes of serum gastrointestinal hormones, Vascular endothelial growth factor and related indexes in patients with gastric cancer [J]. Chin J Gero, 2014, 34 (17): 6859-6860.
[34]	Liu FG, Zhou HM, Xu JM, et al. Relationship between serum levels of Vascular endo-thelial growth factor and Endostatin in patients with gastric carcinoma and clinical-pathological characteristics [J]. Shandong Med, 2009, 49 (25): 11-13.
[35]	Zhu YW, Cheng JL, Qian KQ, et al. Expression of serum VEGF ang P53 in patiens with gastric cancer [J]. Mode Onco, 2007, 15 (3): 375-376.
[36]	Zhou HC, Liu HB, Su L, et al. Seurm levels of VEGF and COX- 2 in gastric cancer [J]. Mode Onco, 2013, 21 (9): 2019-2021.
[37]	Yang YE, Meng QS, Sun XJ. Clinical significance of combined determination of serum CEA, CA724, VEGF and Endostatin in patients with gastric cancer [J]. Med Lab & Clin, 2010, 21 (6): 67-69.
[38]	Zhu GM, Ma L. Clinical Value of Combined Detection of Serum VEGF, CEA and CA724 in Patient with Gastric Cancer [J]. J Mod Lab Med, 2007, 22 (6): 83-85.
[39]	Fang YZ, Chen JG. Application of serum CEA, Cal99 and VEGF in the diagnosis of gastric cancer [J]. J Youjiang Med Colle Nation, 2009, 31 (5): 805-806.
[40]	Li YM, Ren ZHH, Zhang JW. Expression of serum interleukin-6, C-reactive protein and vascularendothelial growth factor in patients with gastric cancer and its clinical significance [J]. J Med Foru, 2022, 42 (5): 68-71.
[41]	Villarejo-Campos P, Padilla-Valverde D, Martin RM, et al. Serum VEGF and VEGF-C values before surgery and after postoperative treatment in gastric cancer [J]. Clin Transl Oncol, 2013, 15 (4): 265-270.
[42]	Bilgiç CI, Tez M. Serum VEGF levels in gastric cancer patients: correlation with clinicopathological parameters [J] Turk J Med Sci. 2015, 45 (1): 112-117.
[43]	Wang SD. Changes of serum VEGF, MMP-9 and endostatin levels in patients with medical gastric cancer and their clinical significance [J]. Shandong Med, 2011, 51 (38): 67-68.
[44]	Xia BX, Li Fan, Xu J, et al. Expression and clinical significance of interleukin-33 and Vascu-lar endothelial growth factor C in gastric carcinoma [J]. Chong Qing Ned, 2016, 46 (15): 2056-2059.
[45]	Yao QQ. Clinical value of serum IL-6, CA724 and VEGF in patients with gastric cancer [J]. Fron Med, 2018, 8 (31): 141-142.
[46]	Liu B, Zhou F, Yang F. Serum bFGF, VEGF and CE were used to predict the efficacy of Apatinib in the treatment of advanced gastric cancer [J]. Abstracts of the world's latest medical information, 2020, 20 (1): 166-167.
[47]	Dong L, Xia M, Shang KX, et al. Changes and clinical significance of serum VEGF, MMP-2 and MMP 9 levels in patients with gastric cancer before and after surgery [J]. J MolDiagn Ther, 2020, 12 (9): 1221-1225.
[48]	Kusakabe T, Nashimoto A, HonmaK, et al. Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach [J]. Histopathology, 2002, 40 (1): 71-79.
[49]	Ito T, Sato K, Maekawa H, et al. Elevated levels of serum fatty acid synthase in patients with gastric carcinoma [J]. Oncol Lett, 2014, 7 (3): 616-620.
[50]	Lin J, Dai HF. Diagnostic significance of levels of serum fatty acid synthase in patients with gastric carcinoma [J]. J Dalian Med Univer, 2014, 36 (5): 475-477.
[51]	Li X. Diagnostic value of serum PG, MG7-Ag, TK1 and Fas in gastric cancer [D]. 2016, Master's degree thesis, Chengdu University of Traditional Chinese medicine.
[52]	Hli Y, Dai SC. Application value of combined detection of PG and FAS in diagnosis of gastric cancer [J]. Int J Lab Med, 2015, (8): 1092-1093.

Cite This Article

Plain Text BibTeX RIS

APA Style

Hou Jianzhang, Zhang Shuli, Yuan Jianlei, Li Hongyan, Hou Zhenjiang. (2023). Research Progress of Serum VEGF and FAS in Prognosis of Gastric Cancer. American Journal of Clinical and Experimental Medicine, 11(2), 39-46. https://doi.org/10.11648/j.ajcem.20231102.13

Copy | Download

ACS Style

Hou Jianzhang; Zhang Shuli; Yuan Jianlei; Li Hongyan; Hou Zhenjiang. Research Progress of Serum VEGF and FAS in Prognosis of Gastric Cancer. Am. J. Clin. Exp. Med. 2023, 11(2), 39-46. doi: 10.11648/j.ajcem.20231102.13

Copy | Download

AMA Style

Hou Jianzhang, Zhang Shuli, Yuan Jianlei, Li Hongyan, Hou Zhenjiang. Research Progress of Serum VEGF and FAS in Prognosis of Gastric Cancer. Am J Clin Exp Med. 2023;11(2):39-46. doi: 10.11648/j.ajcem.20231102.13

Copy | Download

@article{10.11648/j.ajcem.20231102.13,
  author = {Hou Jianzhang and Zhang Shuli and Yuan Jianlei and Li Hongyan and Hou Zhenjiang},
  title = {Research Progress of Serum VEGF and FAS in Prognosis of Gastric Cancer},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {11},
  number = {2},
  pages = {39-46},
  doi = {10.11648/j.ajcem.20231102.13},
  url = {https://doi.org/10.11648/j.ajcem.20231102.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20231102.13},
  abstract = {Vascular endothelial growth factor (VEGF) is an important factor to promote endothelial cell division and angiogenesis. In physiological conditions, the expression level of VEGF in human tissues is very low. Ischemia, hypoxia and many tumors can promote the synthesis and secretion of VEGF, and its expression level is related to the degree of vascularization of tumors, the proliferation, growth and metastasis of tumor cells. Fatty acid synthase (FAS) is a key enzyme for endogenous fatty acid synthesis, which is expressed at a low level in normal tissue cells, while FASN in a variety of tumor cells is continuously highly expressed to meet the energy needs of cell proliferation and the excessive demand for rapid proliferation of tumor cells to form cell membrane lipids. A large amount of research shows that VEGF and FAS play an important role in the development and development of many tumors, and the abnormally high expression in tumor tissue cells is positively correlated with serum VEGF and FAS levels, which is closely related to the prognosis of tumors. Gastric cancer (GC) is one of the most common clinical malignant tumors of the digestive tract, and its incidence and mortality have shown an increasing trend in recent years, and the prognosis is poor, seriously endangering human health. The biological properties of GC are related to the level of VEGF and FAS expression in tissues and serum. This article reviews the research progress of VEGF and FAS, their expression in GC and their prognosis.},
 year = {2023}
}

Copy | Download

TY  - JOUR
T1  - Research Progress of Serum VEGF and FAS in Prognosis of Gastric Cancer
AU  - Hou Jianzhang
AU  - Zhang Shuli
AU  - Yuan Jianlei
AU  - Li Hongyan
AU  - Hou Zhenjiang
Y1  - 2023/04/20
PY  - 2023
N1  - https://doi.org/10.11648/j.ajcem.20231102.13
DO  - 10.11648/j.ajcem.20231102.13
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 39
EP  - 46
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20231102.13
AB  - Vascular endothelial growth factor (VEGF) is an important factor to promote endothelial cell division and angiogenesis. In physiological conditions, the expression level of VEGF in human tissues is very low. Ischemia, hypoxia and many tumors can promote the synthesis and secretion of VEGF, and its expression level is related to the degree of vascularization of tumors, the proliferation, growth and metastasis of tumor cells. Fatty acid synthase (FAS) is a key enzyme for endogenous fatty acid synthesis, which is expressed at a low level in normal tissue cells, while FASN in a variety of tumor cells is continuously highly expressed to meet the energy needs of cell proliferation and the excessive demand for rapid proliferation of tumor cells to form cell membrane lipids. A large amount of research shows that VEGF and FAS play an important role in the development and development of many tumors, and the abnormally high expression in tumor tissue cells is positively correlated with serum VEGF and FAS levels, which is closely related to the prognosis of tumors. Gastric cancer (GC) is one of the most common clinical malignant tumors of the digestive tract, and its incidence and mortality have shown an increasing trend in recent years, and the prognosis is poor, seriously endangering human health. The biological properties of GC are related to the level of VEGF and FAS expression in tissues and serum. This article reviews the research progress of VEGF and FAS, their expression in GC and their prognosis.
VL  - 11
IS  - 2
ER  -

Copy | Download

Author Information

Hou Jianzhang

Department of Hepatobiliary and Pancreatic (Minimally Invasive) Surgery, Cangzhou People's Hospital, Cancer Hospital District, Cangzhou, China
Zhang Shuli

Department of Hepatobiliary and Pancreatic (Minimally Invasive) Surgery, Cangzhou People's Hospital, Cancer Hospital District, Cangzhou, China
Yuan Jianlei

Department of Hepatobiliary and Pancreatic (Minimally Invasive) Surgery, Cangzhou People's Hospital, Cancer Hospital District, Cangzhou, China
Li Hongyan

Department of Medical Technology, Cangzhou Medical College, Cangzhou, China
Hou Zhenjiang

Department of Medical Technology, Cangzhou Medical College, Cangzhou, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Hou Jianzhang, Zhang Shuli, Yuan Jianlei, Li Hongyan, Hou Zhenjiang. (2023). Research Progress of Serum VEGF and FAS in Prognosis of Gastric Cancer. American Journal of Clinical and Experimental Medicine, 11(2), 39-46. https://doi.org/10.11648/j.ajcem.20231102.13

Copy | Download

ACS Style

Hou Jianzhang; Zhang Shuli; Yuan Jianlei; Li Hongyan; Hou Zhenjiang. Research Progress of Serum VEGF and FAS in Prognosis of Gastric Cancer. Am. J. Clin. Exp. Med. 2023, 11(2), 39-46. doi: 10.11648/j.ajcem.20231102.13

Copy | Download

AMA Style

Hou Jianzhang, Zhang Shuli, Yuan Jianlei, Li Hongyan, Hou Zhenjiang. Research Progress of Serum VEGF and FAS in Prognosis of Gastric Cancer. Am J Clin Exp Med. 2023;11(2):39-46. doi: 10.11648/j.ajcem.20231102.13

Copy | Download

@article{10.11648/j.ajcem.20231102.13,
  author = {Hou Jianzhang and Zhang Shuli and Yuan Jianlei and Li Hongyan and Hou Zhenjiang},
  title = {Research Progress of Serum VEGF and FAS in Prognosis of Gastric Cancer},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {11},
  number = {2},
  pages = {39-46},
  doi = {10.11648/j.ajcem.20231102.13},
  url = {https://doi.org/10.11648/j.ajcem.20231102.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20231102.13},
  abstract = {Vascular endothelial growth factor (VEGF) is an important factor to promote endothelial cell division and angiogenesis. In physiological conditions, the expression level of VEGF in human tissues is very low. Ischemia, hypoxia and many tumors can promote the synthesis and secretion of VEGF, and its expression level is related to the degree of vascularization of tumors, the proliferation, growth and metastasis of tumor cells. Fatty acid synthase (FAS) is a key enzyme for endogenous fatty acid synthesis, which is expressed at a low level in normal tissue cells, while FASN in a variety of tumor cells is continuously highly expressed to meet the energy needs of cell proliferation and the excessive demand for rapid proliferation of tumor cells to form cell membrane lipids. A large amount of research shows that VEGF and FAS play an important role in the development and development of many tumors, and the abnormally high expression in tumor tissue cells is positively correlated with serum VEGF and FAS levels, which is closely related to the prognosis of tumors. Gastric cancer (GC) is one of the most common clinical malignant tumors of the digestive tract, and its incidence and mortality have shown an increasing trend in recent years, and the prognosis is poor, seriously endangering human health. The biological properties of GC are related to the level of VEGF and FAS expression in tissues and serum. This article reviews the research progress of VEGF and FAS, their expression in GC and their prognosis.},
 year = {2023}
}

Copy | Download

TY  - JOUR
T1  - Research Progress of Serum VEGF and FAS in Prognosis of Gastric Cancer
AU  - Hou Jianzhang
AU  - Zhang Shuli
AU  - Yuan Jianlei
AU  - Li Hongyan
AU  - Hou Zhenjiang
Y1  - 2023/04/20
PY  - 2023
N1  - https://doi.org/10.11648/j.ajcem.20231102.13
DO  - 10.11648/j.ajcem.20231102.13
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 39
EP  - 46
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20231102.13
AB  - Vascular endothelial growth factor (VEGF) is an important factor to promote endothelial cell division and angiogenesis. In physiological conditions, the expression level of VEGF in human tissues is very low. Ischemia, hypoxia and many tumors can promote the synthesis and secretion of VEGF, and its expression level is related to the degree of vascularization of tumors, the proliferation, growth and metastasis of tumor cells. Fatty acid synthase (FAS) is a key enzyme for endogenous fatty acid synthesis, which is expressed at a low level in normal tissue cells, while FASN in a variety of tumor cells is continuously highly expressed to meet the energy needs of cell proliferation and the excessive demand for rapid proliferation of tumor cells to form cell membrane lipids. A large amount of research shows that VEGF and FAS play an important role in the development and development of many tumors, and the abnormally high expression in tumor tissue cells is positively correlated with serum VEGF and FAS levels, which is closely related to the prognosis of tumors. Gastric cancer (GC) is one of the most common clinical malignant tumors of the digestive tract, and its incidence and mortality have shown an increasing trend in recent years, and the prognosis is poor, seriously endangering human health. The biological properties of GC are related to the level of VEGF and FAS expression in tissues and serum. This article reviews the research progress of VEGF and FAS, their expression in GC and their prognosis.
VL  - 11
IS  - 2
ER  -

Copy | Download